Storia in 3 fonti

IPF biotech Celea gets $180M to follow paths of PureTech's Karuna, Seaport

Celea has corralled $180 million to see if its twist on an approved medicine for idiopathic pulmonary fibrosis can beat the original Roche treatment.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo1 mese fa

Celea has corralled $180 million to see if its twist on an approved medicine for idiopathic pulmonary fibrosis can beat the original Roche treatment.

Celea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.